Rafael Holdings Posts $29.6M FY2026 Loss, $22.1M Cash, Confirms NDA Filing
RFL is trading near its 52-week low of $1.12 (1.8% above the low) on light trading volume (0.2× avg).
Summary
Rafael Holdings reported a $29.6 million net loss for fiscal 2026, with $22.1 million of cash left at July 31, 2026, down from $52.8 million a year earlier, and confirmed its NDA submission for remibetadex in Niemann-Pick Disease Type C.
Key Events · Earnings and Guidance · RFL
-
FY2026 Net Loss of $29.6 Million
Full-year net loss attributable to Rafael Holdings was $29.6 million, or $0.58 per share, versus $30.5 million, or $1.04 per share, a year earlier. The fourth quarter alone lost $9.2 million, or $0.18 per share.
-
Cash Fell to $22.1 Million
Cash and cash equivalents stood at $22.1 million at July 31, 2026, down from $52.8 million at July 31, 2025 — a $30.7 million decline over the year against a $29.6 million net loss.
-
R&D Spending Jumped on Cyclo Consolidation
Full-year R&D rose to $24.3 million from $12.8 million, primarily a $13.4 million increase in Cyclo's R&D following its March 2025 consolidation. G&A fell to $9.7 million from $13.8 million.
-
Going-Concern Risk Flagged
The release's forward-looking statements cite 'our need for additional financing and the substantial doubt about our ability to continue as a going concern.'
Analysis · RFL · Life Sciences
The NDA submission was already public this morning, so the real news here is the fiscal year-end balance sheet: cash fell to $22.1 million from $52.8 million a year earlier, against a full-year net loss of $29.6 million. That burn rate relative to remaining cash is the central issue — the company's own forward-looking statements flag substantial doubt about its ability to continue as a going concern, and management is pointing to a Priority Review Voucher as a potential source of non-dilutive capital. The next hard checkpoint is the FDA's 60-day decision from receipt on whether to file the NDA and grant Priority Review.
How filings like this one have moved
In the 30 days to Nov 12, 2026, 37% of the 3595 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, RFL was trading at $1.14 on NYSE in the Life Sciences sector, with a market capitalization of approximately $62.9M. The 52-week trading range was $1.12 to $3.96. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.